A study has found that certain proteins that determine blood type may affect the severity of COVID-19.
On the 7th (local time), a joint research team from King’s College London University’s Institute of Psychiatry, Psychology and Neuroscience (IoPPN) and the University of Cambridge found that a protein that plays an important role in determining the ABO blood group was related to the severe progression of COVID-19. said that there appears to be
The research team analyzed more than 3,000 proteins through 5504 genomes and found six proteins that cause severe severe or death from COVID-19 and eight proteins that protect once morest severe illness or death.
As a result of the analysis, ‘ABO’, a protein that determines the blood type, was included among the proteins that cause severe seriousness or death from COVID-19. The research team previously explained that there is a high possibility that there is a correlation between blood type and the likelihood of death from COVID-19.
In addition to the ABO protein, six proteins, including GCNT4, CD207, RAB14, C1GALT1C1, and FAAH2, were solely associated with an increased risk of hospitalization for COVID-19. The researchers also found that higher levels of endocannabinoid enzymes may increase the risk of hospitalization.
“While our study does not associate a specific blood type with a serious risk of COVID-19, we found in previous studies that people with type A were more likely to be positive for COVID-19,” the researchers said. “He said.
“This study is the first study to evaluate the association between a large number of blood proteins and COVID-19,” he said.
There have been several studies that have previously tracked the correlation between type A carriers and COVID-19.
In March of last year, a research team at Harvard Medical School, Brigham and Women’s Hospital in the U.S., announced a study result that “type A is more susceptible to COVID-19.” .
Alisie Palmos, a researcher at IoPPN at King’s College London, said: “This family of proteins will be an important first step in discovering potentially valuable targets for the treatment of novel COVID-19.”
©Dailyan Co., Ltd. Unauthorized reproduction and redistribution prohibited
